United Therapeutics Corporation

UTHR's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

UTHR Growth rates comparisons

Looking into United Therapeutics growth rates, revenue grew by 6.76 % in the third quarter of 2025 from the same quarter a year ago.

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.29 %

United Therapeutics's net income grew by 9.58 % in third quarter of 2025 year on year, above company average,

• More on UTHR's Growth

UTHR's Valuation comparisons

United Therapeutics
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

United Therapeutics PEG ratio is at 0.95 United Therapeutics realized cash reduction of $ -4.52 per share in trailing twelve-month period.

Company

16.49

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 6.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

• More on UTHR's Valuation

Total Debt (Millions $)	-
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	2,678,425
Net Income/Employee (TTM) $	1,088,784
Receivable Turnover (TTM)	9.79
Tangible Book Value (Per Share $)	136.86

UTHR's Valuation comparisons

United Therapeutics
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

United Therapeutics PEG ratio is at 0.95 United Therapeutics realized cash outflow of $ -4.52per share in trailing twelve-month period.

Company

16.49

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 6.63.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

United Therapeutics Price to Book Ratio is at 3.15 lower than Industry Avg. of 39.15. and higher than S&P 500 Avg. of 0.02

• More on UTHR's Valuation

• Market Capitalization (Millions $)	20,749
• Shares Outstanding (Millions)	47
• Employees	1,168
• Revenues (TTM) (Millions $)	3,128
• Net Income (TTM) (Millions $)	1,272
• Cash Flow (TTM) (Millions $)	-214
• Capital Exp. (TTM) (Millions $)	-440
• Total Debt (Millions $)	-
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	2,678,425
• Net Income/Employee(TTM) $	1,088,784
• Receivable Turnover Ratio (TTM)	9.79
• Tangible Book Value (Per Share $)	136.86

• Market Capitalization (Millions $)	20,749
• Shares Outstanding (Millions)	47
• Employees	1,168
• Revenues (TTM) (Millions $)	3,128
• Net Income (TTM) (Millions $)	1,272
• Cash Flow (TTM) (Millions $)	-214
• Capital Exp. (TTM) (Millions $)	-440

UTHR's Profitability Comparisons

United Therapeutics achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in third quarter of 2025 to 48.59 % from 45.64 % in II. Quarter.

United Therapeutics net profit margin of 42.36 % is currently ranking no. 5 in Major Pharmaceutical Preparations industry, ranking no. 10 in Healthcare sector and number 93 in S&P 500.

Profitability by Segment
Tyvaso DPI	83.55 %
Nebulized Tyvaso	95.28 %
Remodulin	89.59 %
Orenitram	94.81 %
Unituxin	92.48 %
Adcirca	54.64 %
Total	42.36 %

	*Ratio*
• Capital Ratio (MRQ)	6.4
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	0.12
• Asset Turnover Ratio (TTM)	0.41
• Inventory Turnover Ratio (TTM)	2.13

UTHR's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.